These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 2931519)

  • 1. Modulation of macrophage-lymphocyte interactions by the antiarthritic gold compound, auranofin.
    Griswold DE; Lee JC; Poste G; Hanna N
    J Rheumatol; 1985 Jun; 12(3):490-7. PubMed ID: 2931519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suppressed IL-2 production and response in AA rats: role of suppressor cells and the effect of auranofin treatment.
    Lee JC; Rebar L; Demuth S; Hanna N
    J Rheumatol; 1985 Oct; 12(5):885-91. PubMed ID: 2935633
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective immunomodulation by the antineoplastic agent mitoxantrone. II. Nonspecific adherent suppressor cells derived from mitoxantrone-treated mice.
    Fidler JM; DeJoy SQ; Smith FR; Gibbons JJ
    J Immunol; 1986 Apr; 136(8):2747-54. PubMed ID: 2937837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiarthritic and immunoregulatory activity of spirogermanium.
    DiMartino MJ; Lee JC; Badger AM; Muirhead KA; Mirabelli CK; Hanna N
    J Pharmacol Exp Ther; 1986 Jan; 236(1):103-10. PubMed ID: 2934544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of human immune responsiveness in vitro by auranofin.
    Salmeron G; Lipsky PE
    J Rheumatol Suppl; 1982; 8():25-31. PubMed ID: 6813487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. B lymphocyte function in patients with rheumatoid arthritis: impact of regulatory T lymphocytes and macrophages--modulation by antirheumatic drugs.
    Petersen J
    Dan Med Bull; 1988 Apr; 35(2):140-57. PubMed ID: 3282810
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The effect of auranofin on lymphocyte functions in vitro].
    Strejcek J; Jíra M; Horký J
    Cas Lek Cesk; 1985 Aug; 124(33):1045-7. PubMed ID: 3928163
    [No Abstract]   [Full Text] [Related]  

  • 8. [Generation of human peripheral blood suppressor cell activity by auranofin].
    Kobayashi K; Sato H; Sekine F; Ohno I; Ohseto Y; Hamai T; Negishi M; Takahashi T
    Arerugi; 1982 Sep; 31(9):948-55. PubMed ID: 6217798
    [No Abstract]   [Full Text] [Related]  

  • 9. Auranofin, an immunosuppressive drug, inhibits MHC class I and MHC class II pathways of antigen presentation in dendritic cells.
    Han S; Kim K; Song Y; Kim H; Kwon J; Lee YH; Lee CK; Lee SJ; Ha N; Kim K
    Arch Pharm Res; 2008 Mar; 31(3):370-6. PubMed ID: 18409052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased sensitivity of tumor-bearing host macrophages to interleukin-10: a counter-balancing action to macrophage-mediated suppression.
    Alleva DG; Burger CJ; Elgert KD
    Oncol Res; 1994; 6(4-5):219-28. PubMed ID: 7841545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Defective antigen presentation to a cloned T helper cell by macrophages from burned mice can be restored with interleukin-1.
    Kupper TS; Green DR; Durum SK; Baker CC
    Surgery; 1985 Aug; 98(2):199-206. PubMed ID: 3161195
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synergistic inhibition of T cell proliferation by gold sodium thiomalate and auranofin.
    Hashimoto K; Whitehurst CE; Lipsky PE
    J Rheumatol; 1994 Jun; 21(6):1020-6. PubMed ID: 7932408
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Periplocoside E, an effective compound from Periploca sepium Bge, inhibited T cell activation in vitro and in vivo.
    Zhu YN; Zhao WM; Yang YF; Liu QF; Zhou Y; Tian J; Ni J; Fu YF; Zhong XG; Tang W; Zhou R; He PL; Li XY; Zuo JP
    J Pharmacol Exp Ther; 2006 Feb; 316(2):662-9. PubMed ID: 16204471
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclosporine inhibits macrophage-mediated antigen presentation.
    Palay DA; Cluff CW; Wentworth PA; Ziegler HK
    J Immunol; 1986 Jun; 136(12):4348-53. PubMed ID: 3486899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of in vitro and in vivo effects of gold compounds on leukocyte function: possible mechanisms of action.
    Wolach B; DeBoard JE; Coates TD; Baehner RL; Boxer LA
    J Lab Clin Med; 1982 Jul; 100(1):37-44. PubMed ID: 6283001
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro effects of an antitumor antibiotic, ascofuranone, on the murine immune system.
    Magae J; Suzuki S; Nagai K; Yamasaki M; Ando K; Tamura G
    Cancer Res; 1986 Mar; 46(3):1073-8. PubMed ID: 3080231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cellular antiproliferative action exerted by auranofin.
    Simon TM; Kunishima DH; Vibert GJ; Lorber A
    J Rheumatol Suppl; 1979; 5():91-7. PubMed ID: 226702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence for effects of interleukin 4 (B cell stimulatory factor 1) on macrophages: enhancement of antigen presenting ability of bone marrow-derived macrophages.
    Zlotnik A; Fischer M; Roehm N; Zipori D
    J Immunol; 1987 Jun; 138(12):4275-9. PubMed ID: 3495588
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lyt-2+ cells. Requirements for concanavalin A-induced proliferation and interleukin 2 production.
    Kern DE; Lachmann LB; Greenberg PD
    J Immunol; 1987 Nov; 139(9):2880-7. PubMed ID: 2959723
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of action of auranofin: effects on humoral immune response.
    Walz DT; Dimartino MJ; Griswold DE
    J Rheumatol Suppl; 1982; 8():32-6. PubMed ID: 6813489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.